Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Show Only Open Trials
1.

Gilead 0119: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Previously Treated Chronic Lymphocytic Leukemia (CLL)
  • Protocol ID: Gilead 0119
2.

A Phase Ib/IIa Study of Romidepsin in Combination with Lenalidomide in Adults with Relapsed or Refractory Lymphomas and Myeloma

  • Study Status: Open to Enrollment
  • Sponsor: Memorial Sloan-Kettering Cancer Center
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoma and Multiple Myeloma
3.

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid Malignancies

  • Study Status: Open to Enrollment
  • Sponsor: OncoMed
  • Disease Status and/or Stage: Relapsed or Refractory Lymphoid Malignancies, Including Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Transformed Mycosis Fungoides (MF), or Sezary Syndrome
  • Protocol ID: 52M51-001
4.

A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients with CLL

  • Study Status: Open to Enrollment
  • Sponsor: Weill Cornell Medical College
  • Disease Status and/or Stage: Untreated CLL
5.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Patients with Previously Treated Chronic Lymphocytic Leukemia

  • Study Status: Open to Enrollment
  • Sponsor: Gilead Sciences, Inc.
  • Disease Status and/or Stage: Previously Treated Chronic Lymphocytic Leukemia (CLL)
  • Protocol ID: 0116

Top of page